Related Experiment Videos

[New challenges in the treatment of dyslipidemia and cardiovascular risk]

R López Menchaca1, C Suárez Fernández

  • 1Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España.

Revista Clinica Espanola
|June 2, 2009
PubMed

Insights

Statins reduce cardiovascular disease but residual risk remains. Combining statins with niacin offers a promising strategy for comprehensive dyslipidemia treatment and further CV risk reduction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Lipidology

Context:

  • Cardiovascular (CV) disease remains a leading cause of mortality despite statin therapy.
  • Residual CV risk persists even with optimal statin treatment.
  • Novel therapeutic strategies are needed to further mitigate CV risk.

Purpose:

  • To review the role of HDL cholesterol and triglycerides in CV risk.
  • To evaluate potential agents for add-on therapy to statins.
  • To explore the synergistic effects of combination therapy for dyslipidemia.

Summary:

  • Statins offer significant CV risk reduction but do not eliminate it.
  • Fibrates effectively lower triglycerides; niacin impacts LDL, triglycerides, and HDL cholesterol.
  • Combining statins with niacin presents a potential future approach for comprehensive dyslipidemia management.

Impact:

  • Niacin's broad lipid-modifying effects make it a strong candidate for combination therapy.
  • Statin-niacin combination may offer enhanced CV risk reduction beyond statins alone.
  • This approach targets multiple lipid parameters for improved cardiovascular outcomes.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...